The initiation of a second CART programme for Novartis is encouraging and follows Oxford BioMedica’s recent MHRA approval to manufacture at its Yarnton facility. The indication of the second programme is undisclosed and we leave our forecasts unchanged until additional information is provided. We continue to look forward to the first programme, CTL019 for acute lymphoblastic leukaemia, being filed by Novartis in 2017. We remain at Buy with a target price of 11p.
